Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations
![](/bundles/mdpisciprofileslink/img/unknown-user.png)
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsSummary
In this review the authors discuss about the status about various types of vaccines that have been used in the management of pancreatic cancer. They discussed in detail about the current application and challenges related to the use of mRNA vaccines in pancreatic cancer management.
Strengths – This appears to be the most comprehensive review of vaccines in pancreatic cancer in the last few years.
General comments about the study
1.This is a well written comprehensive review of vaccines in the management of pancreatic cancer.
Other comments
1. Consider adding images to describe the mechanisms of each of the vaccine types if possible.
2. Discuss about complications related to use of vaccines in immunotherapy.
3. Please discuss about the stage of malignancy where vaccines are most effective.
4. What are the challenges related to the use of vaccines in patients with early stage tumors?
5. Can you briefly discuss how a particular antigen or mRNA is chosen as a vaccine target?
6. Briefly explain why and how vaccines work in inducing immunity while intrinsic cancer cells fail to do so.
7. Please maintain the same table format in both the tables. Please include year of study completion in table 2 as well.
8. Consider editing the manuscript to focus more on mRNA vaccines as they are the future of vaccines with respect to Pancreatic cancer.
Minor comments
1.Minor typos need to be addressed.
Author Response
Dear Reviewers, Thank you for taking the time to review our manuscript. A detailed response is annotated and attached:
Author Response File: Author Response.pdf
Reviewer 2 Report
Comments and Suggestions for AuthorsThis is timely and relevant manuscript. An informative read.
Minor comments:
Line 28: please correct ‘cause of’ to ‘cause for’
Line 33: please correct ‘hindering early prognosis and treatment interventions’ to ‘hindering attempts at cure'
Line 37: i would add ‘borderline-resectable’, too
Line 58: when you say “pancreatic cancer” do you mean ‘PDAC’? If so, please be consistent.
Author Response
Thank you for taking the time to review this manuscript. We have made the changes requested in the paper.